On September 22, 2025, the White House held a briefing where the President and FDA Commissioner made claims about paracetamol (acetaminophen) and leucovorin's relationship to autism spectrum disorder. The officials discouraged paracetamol use during pregnancy, citing research linking prenatal exposure to neurodevelopmental disorders. This announcement bypassed the FDA's normal deliberate review process that typically includes stakeholder input.
Federal prescribing recommendations traditionally follow transparent processes involving FDA scientists and public consultation. The White House briefing represented a departure from established protocols for communicating drug safety information. Paracetamol is widely used during pregnancy for pain and fever management, making any safety communications particularly significant for expectant mothers and healthcare providers.
The briefing selectively cited research purporting links between prenatal paracetamol exposure and autism spectrum disorders. However, the scientific evidence on this relationship remains mixed and contested within the medical community. The FDA had not completed its standard review process before the public statements were made.
The unprecedented approach raises questions about the integrity of drug safety communications and could affect physician prescribing patterns and patient behavior. Pregnant women may now avoid necessary pain management, while healthcare providers face uncertainty about evidence-based recommendations. The incident highlights tensions between political messaging and established regulatory science protocols.